BIB – ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (BIB) is a Trading--Leveraged Equity ETF, issued by ProShares, $90.6M in assets, 0.95% expense ratio.
Returns as of Oct 23, 2026: 1 week +5.0%, 1 year +62.9%.
Aims for daily returns consistent with Nasdaq Biotechnology Index. Invests in financial instruments for 2x leveraged exposure.
Top holdings
- VRTX – Vertex Pharmaceuticals Inc, 5.8%
- GILD – Gilead Sciences Inc, 5.6%
- AMGN – Amgen Inc, 5.4%
- REGN – Regeneron Pharmaceuticals Inc, 4.0%
- AZN – AstraZeneca PLC ADR, 2.9%
- ALNY – Alnylam Pharmaceuticals Inc, 2.5%
- INSM – Insmed Inc, 1.8%
- BIIB – Biogen Inc, 1.3%
- ARGX – argenx NV ADR, 1.2%
- RVMD – Revolution Medicines Inc, 1.2%
- ILMN – Illumina Inc, 1.1%
- INCY – Incyte Corporation, 1.1%
- UTHR – United Therapeutics Corporation, 1.0%
- MEDP – Medpace Holdings Inc, 0.9%
- RPRX – Royalty Pharma Plc, 0.9%
- MRNA – Moderna Inc, 0.9%
- ROIV – Roivant Sciences Ltd, 0.8%
- VTRS – Viatris Inc, 0.8%
- BBIO – BridgeBio Pharma Inc, 0.8%
- GH – Guardant Health Inc, 0.8%
- NBIX – Neurocrine Biosciences Inc, 0.7%
- SMMT – Summit Therapeutics PLC, 0.7%
- ASND – Ascendis Pharma AS, 0.7%
- IONS – Ionis Pharmaceuticals Inc, 0.6%
- SNY – Sanofi ADR, 0.6%